Q-omics provides the consensus-scored NUP50P1 profile across patient tissues and cancer cell-line models. NUP50P1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NUP50P1 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, NUP50P1 RNA expression shows 8,663 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, HNSC, and TGCT as cancer lineages where NUP50P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUP50P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUP50P1 survival associations across molecular data types. NUP50P1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUP50P1 RNA expression–survival associations across cancer types. High NUP50P1 expression shows unfavorable associations in LIHC, MESO, UCS and COAD, but favorable associations in SKCM and PAAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for NUP50P1 RNA expression.
This table summarizes NUP50P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for NUP50P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUP50P1 shows lower tumor expression in PAAD, KICH and THCA and higher tumor expression in HNSC, LUAD and LUSC. The HNSC box plot shows higher NUP50P1 RNA expression in tumor versus normal tissue (log2 FC = +0.041, t-test p = .006).
This table shows molecular features associated with NUP50P1 in patient tissues and cancer cell lines. In patient samples, NUP50P1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
